Urinary metabolic phenotyping for Alzheimer’s disease
暂无分享,去创建一个
N. Kurbatova | A. Brazma | H. Soininen | P. Mecocci | B. Vellas | M. Tsolaki | I. Kloszewska | S. Lovestone | D. Aarsland | P. Proitsi | A. Nevado-Holgado | J. Nicholson | E. Holmes | S. Snowden | Matthew R. Lewis | C. Legido-Quigley | A. Hye | M. Gómez-Romero | B. Jiménez | J. Pearce | L. Whiley | E. Chekmeneva | T. Kimhofer | N. Ashton | Manik Garg | E. D’Hondt | B. Liu | M. Lewis | M. Gómez‐Romero | E. D'Hondt | Torben Kimhofer | Abdul Hye | María Gómez‐Romero | Luke Whiley
[1] Noureddin Sadawi,et al. The nPYc-Toolbox, a Python module for the pre-processing, quality-control and analysis of metabolic profiling datasets , 2019, Bioinform..
[2] G. Brewer,et al. Global Metabolic Shifts in Age and Alzheimer’s Disease Mouse Brains Pivot at NAD+/NADH Redox Sites , 2019, Journal of Alzheimer's disease : JAD.
[3] J. Nicholson,et al. Systematic Isolation and Structure Elucidation of Urinary Metabolites Optimized for the Analytical-Scale Molecular Profiling Laboratory , 2019, Analytical Chemistry.
[4] Beatrice Aramini,et al. A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology , 2019, Scientific Reports.
[5] A. Garg,et al. Untargeted metabolomics reveals N, N, N-trimethyl-L-alanyl-L-proline betaine (TMAP) as a novel biomarker of kidney function , 2019, Scientific Reports.
[6] D. Campion,et al. SORL1 genetic variants and Alzheimer disease risk: a literature review and meta-analysis of sequencing data , 2019, Acta Neuropathologica.
[7] Isabel Meister,et al. Challenges, progress and promises of metabolite annotation for LC-MS-based metabolomics. , 2019, Current opinion in biotechnology.
[8] Dag Aarsland,et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration , 2019, Acta neuropathologica communications.
[9] Helen E. Parkinson,et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019 , 2018, Nucleic Acids Res..
[10] Xianlin Han,et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome , 2018, Alzheimer's & Dementia.
[11] S. An,et al. Gut Microbiota and Their Neuroinflammatory Implications in Alzheimer’s Disease , 2018, Nutrients.
[12] Fedor V. Karginov,et al. Antagonistic and cooperative AGO2-PUM interactions in regulating mRNAs , 2018, Scientific Reports.
[13] H. Meltzer,et al. Neurosteroid pregnenolone sulfate, alone, and as augmentation of lurasidone or tandospirone, rescues phencyclidine-induced deficits in cognitive function and social interaction , 2018, Behavioural Brain Research.
[14] M. Buffelli,et al. Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease , 2018, Acta neuropathologica communications.
[15] Tiangang Li,et al. Bile acids regulate cysteine catabolism and glutathione regeneration to modulate hepatic sensitivity to oxidative injury. , 2018, JCI insight.
[16] L. Ferrucci,et al. Evidence for brain glucose dysregulation in Alzheimer's disease , 2018, Alzheimer's & Dementia.
[17] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[18] T. Iwaki,et al. Comparative profiling of cortical gene expression in Alzheimer’s disease patients and mouse models demonstrates a link between amyloidosis and neuroinflammation , 2017, Scientific Reports.
[19] G. Kemmler,et al. Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer’s disease , 2017, Metabolomics.
[20] Sterling C. Johnson,et al. Gut microbiome alterations in Alzheimer’s disease , 2017, Scientific Reports.
[21] Philip Scheltens,et al. Blood-based metabolic signatures in Alzheimer's disease , 2017, Alzheimer's & dementia.
[22] A. Zhang,et al. High-Throughput Metabolomics for Discovering Potential Metabolite Biomarkers and Metabolic Mechanism from the APPswe/PS1dE9 Transgenic Model of Alzheimer's Disease. , 2017, Journal of proteome research.
[23] J. Estep,et al. The RacGAP β-Chimaerin is essential for cerebellar granule cell migration , 2017, Scientific Reports.
[24] J. Belisle,et al. Elucidating the Structure of N1-Acetylisoputreanine: A Novel Polyamine Catabolite in Human Urine , 2017, ACS omega.
[25] D. Absher,et al. Genome- and CD4+ T-cell methylome-wide association study of circulating trimethylamine-N-oxide in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). , 2017, Journal of nutrition & intermediary metabolism.
[26] C. Hölscher,et al. Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer’s Disease , 2017, Metabolites.
[27] K. Lunetta,et al. Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans , 2017, Alzheimer's & Dementia.
[28] M. Lovell,et al. Multiregional analysis of global 5‐methylcytosine and 5‐hydroxymethylcytosine throughout the progression of Alzheimer's disease , 2017, Journal of neurochemistry.
[29] Michelle K. Lupton,et al. Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis , 2017, Alzheimer's & Dementia.
[30] P. Snyder,et al. Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic , 2017, Alzheimer's & Dementia.
[31] J. S. Smith,et al. Ab initio calculation of energy levels for phosphorus donors in silicon , 2016, Scientific Reports.
[32] K. Blennow,et al. The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.
[33] P. Elliott,et al. Development and Application of Ultra-Performance Liquid Chromatography-TOF MS for Precision Large Scale Urinary Metabolic Phenotyping. , 2016, Analytical chemistry.
[34] V. Gudnason,et al. Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals , 2016, Alzheimer's & Dementia.
[35] K. Blennow,et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.
[36] D. Wesson,et al. Alterations of the volatile metabolome in mouse models of Alzheimer’s disease , 2016, Scientific Reports.
[37] G. Breen,et al. Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins , 2016, Translational psychiatry.
[38] A. Lindsay,et al. Realising the Potential of Urine and Saliva as Diagnostic Tools in Sport and Exercise Medicine , 2016, Sports Medicine.
[39] Youhe Gao,et al. Urinary Biomarkers of Brain Diseases , 2015, Genom. Proteom. Bioinform..
[40] M. Nalls,et al. Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer’s Disease , 2015, Front. Neurol..
[41] K. Kashiwagi,et al. Evaluation of dementia by acrolein, amyloid-β and creatinine. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[42] L. Moezi,et al. The effects of intra-dorsal hippocampus infusion of pregnenolone sulfate on memory function and hippocampal BDNF mRNA expression of biliary cirrhosis-induced memory impairment in rats , 2015, Neuroscience.
[43] Christian Gieger,et al. Genome-Wide Association Study with Targeted and Non-targeted NMR Metabolomics Identifies 15 Novel Loci of Urinary Human Metabolic Individuality , 2015, PLoS genetics.
[44] Wen Dong,et al. The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment , 2015, Journal of Clinical Neuroscience.
[45] Yumei Li,et al. Combining serum and urine biomarkers in the early diagnosis of mild cognitive impairment that evolves into Alzheimer’s disease in patients with the apolipoprotein E ε4 genotype , 2015, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[46] Yuliya V. Karpievitch,et al. Metabolomics Data Normalization with EigenMS , 2014, PloS one.
[47] M. Spraul,et al. Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. , 2014, Analytical chemistry.
[48] D. Wishart,et al. Development of isotope labeling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease. , 2014, Journal of proteome research.
[49] Magda Tsolaki,et al. Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis , 2014, PLoS medicine.
[50] N. Kitamura,et al. Genes associated with the progression of neurofibrillary tangles in Alzheimer's disease , 2014, Translational Psychiatry.
[51] Stefan Teipel,et al. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease , 2014, Alzheimer's & Dementia.
[52] Olivier Colliot,et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. , 2014, Biochemical pharmacology.
[53] R. Bruick,et al. F-box and leucine-rich repeat protein 5 (FBXL5): sensing intracellular iron and oxygen. , 2014, Journal of inorganic biochemistry.
[54] Derick R. Peterson,et al. Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.
[55] Christoph Steinbeck,et al. Genome-Wide Association Study of Metabolic Traits Reveals Novel Gene-Metabolite-Disease Links , 2014, PLoS genetics.
[56] K. Roszkowski. Oxidative DNA damage--the possible use of biomarkers as additional prognostic factors in oncology. , 2014, Frontiers in bioscience.
[57] Harald Hampel,et al. Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease , 2014, Neuropsychopharmacology.
[58] Wei Liu,et al. CORRIGENDUM: Biodegradation-inspired bioproduction of methylacetoin and 2-methyl-2,3-butanediol , 2013, Scientific Reports.
[59] T. Toyo’oka,et al. Metabolic profiling of Alzheimer's disease brains , 2013, Scientific Reports.
[60] M. Pericak-Vance,et al. Independent and epistatic effects of variants in VPS10-d receptors on Alzheimer disease risk and processing of the amyloid precursor protein (APP) , 2013, Translational Psychiatry.
[61] S. Niida,et al. NMR-based metabolomics of urine in a mouse model of Alzheimer’s disease: identification of oxidative stress biomarkers , 2013, Journal of clinical biochemistry and nutrition.
[62] P. S. St George-Hyslop,et al. Vps10 Family Proteins and the Retromer Complex in Aging-Related Neurodegeneration and Diabetes , 2012, The Journal of Neuroscience.
[63] C. Reitz. The role of intracellular trafficking and the VPS10d receptors in Alzheimer's disease. , 2012, Future neurology.
[64] J. Nicholson,et al. Host-Gut Microbiota Metabolic Interactions , 2012, Science.
[65] J. Nicholson,et al. Genetic determinants of metabolism in health and disease: from biochemical genetics to genome-wide associations , 2012, Genome Medicine.
[66] S. Correia,et al. Metabolic Alterations Induced by Sucrose Intake and Alzheimer’s Disease Promote Similar Brain Mitochondrial Abnormalities , 2012, Diabetes.
[67] Andrey A. Shabalin,et al. Matrix eQTL: ultra fast eQTL analysis via large matrix operations , 2011, Bioinform..
[68] M. Şeneş,et al. Urinary 8-hydroxy-2′-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer’s disease , 2012, Clinical chemistry and laboratory medicine.
[69] J. Marchini,et al. Genotype Imputation with Thousands of Genomes , 2011, G3: Genes | Genomes | Genetics.
[70] Peter Donnelly,et al. A Genome-Wide Metabolic QTL Analysis in Europeans Implicates Two Loci Shaped by Recent Positive Selection , 2011, PLoS genetics.
[71] Xianlin Han,et al. Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics , 2011, PloS one.
[72] J. Loscalzo. Lipid metabolism by gut microbes and atherosclerosis. , 2011, Circulation research.
[73] J. Newton,et al. Functional capacity is significantly impaired in primary biliary cirrhosis and is related to orthostatic symptoms , 2011, European journal of gastroenterology & hepatology.
[74] Christian Gieger,et al. A genome-wide association study of metabolic traits in human urine , 2011, Nature Genetics.
[75] J. T. Greenamyre,et al. Mitochondrial iron metabolism and its role in neurodegeneration. , 2010, Journal of Alzheimer's disease : JAD.
[76] A. Paterson,et al. Genome-Wide Association Identifies the ABO Blood Group as a Major Locus Associated With Serum Levels of Soluble E-Selectin , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[77] A. Simmons,et al. AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease , 2009, Annals of the New York Academy of Sciences.
[78] A. Simmons,et al. MRI Measures of Alzheimer's Disease and the AddNeuroMed Study , 2009, Annals of the New York Academy of Sciences.
[79] A. Blamire,et al. Cognitive impairment in primary biliary cirrhosis: Symptom impact and potential etiology , 2008, Hepatology.
[80] S. Lovestone,et al. Diagnosing Alzheimer's disease—non‐clinicians and computerised algorithms together are as accurate as the best clinical practice , 2007, International journal of geriatric psychiatry.
[81] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[82] G. Hu,et al. Long-term D-galactose injection combined with ovariectomy serves as a new rodent model for Alzheimer's disease. , 2007, Life sciences.
[83] Ying Zhang,et al. HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..
[84] S. Lovestone,et al. Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.
[85] Tom Fawcett,et al. An introduction to ROC analysis , 2006, Pattern Recognit. Lett..
[86] R. Abagyan,et al. METLIN: A Metabolite Mass Spectral Database , 2005, Therapeutic drug monitoring.
[87] Ruben Abagyan,et al. A Metabolite Mass Spectral Database , 2005 .
[88] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[89] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[90] D. Abrous,et al. Pregnenolone Sulfate and Aging of Cognitive Functions: Behavioral, Neurochemical, and Morphological Investigations , 2001, Hormones and Behavior.
[91] Tin Kam Ho,et al. The Random Subspace Method for Constructing Decision Forests , 1998, IEEE Trans. Pattern Anal. Mach. Intell..
[92] W. Griffiths,et al. The identification of novel steroid N-acetylglucosaminides in the urine of pregnant women , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[93] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[94] S. Matern,et al. Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans. , 1992, The Journal of clinical investigation.
[95] L. Romanoff,et al. Effect of age on pregnanediol excretion by men. , 1970, Journal of gerontology.